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Background: Colorectal cancer (CRC) is characterised by hypoxia, which activates gene transcription through
hypoxia-inducible factors (HIF), as well as by expression of epidermal growth factor (EGF) and EGF receptors,
targeting of which has been demonstrated to provide therapeutic benefit in CRC. Although EGF has been
demonstrated to induce expression of angiogenic mediators, potential interactions in CRC between EGF-mediated
signalling and the hypoxia/HIF pathway remain uncharacterised.
Methods: PCR-based profiling was applied to identify angiogenic genes in Caco-2 CRC cells regulated by hypoxia,
the hypoxia mimetic dimethyloxallylglycine (DMOG) and/or EGF. Western blotting was used to determine the role
of HIF-1alpha, HIF-2alpha and MAPK cell signalling in mediating the angiogenic responses.
Results: We identified a total of 9 angiogenic genes, including angiopoietin-like (ANGPTL) 4, ephrin (EFNA) 3,
transforming growth factor (TGF) β1 and vascular endothelial growth factor (VEGF), to be upregulated in a HIF
dependent manner in Caco-2 CRC cells in response to both hypoxia and the hypoxia mimetic dimethyloxallylglycine
(DMOG). Stimulation with EGF resulted in EGFR tyrosine autophosphorylation, activation of p42/p44 MAP kinases and
stabilisation of HIF-1α and HIF-2α proteins. However, expression of 84 angiogenic genes remained unchanged in
response to EGF alone. Crucially, addition of DMOG in combination with EGF significantly increased expression of a
further 11 genes (in addition to the 9 genes upregulated in response to either DMOG alone or hypoxia alone). These
additional genes included chemokines (CCL-11/eotaxin-1 and interleukin-8), collagen type IV α3 chain, integrin β3
chain, TGFα and VEGF receptor KDR.
Conclusion: These findings suggest that although EGFR phosphorylation activates the MAP kinase signalling and
promotes HIF stabilisation in CRC, this alone is not sufficient to induce angiogenic gene expression. In contrast, HIF
activation downstream of hypoxia/DMOG drives expression of genes such as ANGPTL4, EFNA3, TGFβ1 and VEGF.
Finally, HIF activation synergises with EGF-mediated signalling to additionally induce a unique sub-group of candidate
angiogenic genes. Our data highlight the complex interrelationship between tumour hypoxia, EGF and angiogenesis in
the pathogenesis of CRC.
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Colorectal cancer (CRC) is the third most common cancer
worldwide, with an estimated 530,000 patients dying from
the condition each year [1]. Biological changes underlying
malignant transformation are complex, but key events
such as angiogenesis, induced in part by alterations in
oxygen tension and growth factors, represent critical
milestones in tumour progression, self-preservation and
survival [2,3]. Low oxygen tension (hypoxia) plays a
pivotal role in cancer, and low intra-tumoural oxygen
tensions (below 30 mmHg, approximately 4% O2) have
been demonstrated in many solid tumours, including CRC
[4,5]. The Hypoxia Inducible Factor (HIF) family of tran-
scription factors is central to the homeostatic mechanisms
involved in the cellular response to hypoxic stress, regula-
ting genes involved in nutritional stress, tumour metabo-
lism, invasion, cell death and angiogenesis, including the
key angiogenic molecule vascular endothelial growth
factor (VEGF) [6,7]. Levels of HIF proteins increase in
hypoxic conditions (generally at below 5% O2) due to
increased stability, as a consequence of the inactivity of
oxygen-dependent HIF hydroxylase enzymes [8-10]. In
CRC, increased HIF expression correlates with carcino-
genesis [11,12], tumour and lymphovascular invasion, liver
metastasis [13] and VEGF expression [14], as well as with
more advanced tumour stage at diagnosis and poorer
prognosis [15]. Furthermore, Imamura et al. reported a
statistically significant correlation between HIF-1α expres-
sion and both VEGF and microvessel density [16], while
both Yoshimura et al. and Cleven et al. found poor prog-
nosis to correlate with increased HIF-2α [17,18].
In addition to the important role of hypoxia/HIF in
CRC, over-expression of epidermal growth factor (EGF)
receptor (EGFR/HER-1) has been demonstrated in ap-
proximately 70-75% of CRC [19]. EGF signalling is
not only capable of potent mitogenic and tumourigenic
effects, but also stimulates angiogenesis in human solid
tumours [20], through direct effects upon the endothe-
lium of new vessels [21], or indirectly by altering expres-
sion of positive and negative regulators of angiogenesis
by tumours. For example, studies with glioma, gastric
and prostate cancer cells demonstrated increased VEGF
expression following EGFR stimulation [20,22,23]. Con-
versely, inhibition of EGFR with antibodies or tyrosine
kinase inhibitors resulted in abrogation of neovasculari-
sation by downregulating VEGF and interleukin-8 (IL8)
through repression of phosphoinositide 3-kinase (PI3K)/
Akt signalling [23-25]. Furthermore, animal models have
confirmed the inhibitory effects of EGFR antagonists,
and these favourable results have been translated to the
clinical application in metastatic CRC of therapies tar-
geting EGFR, namely the monoclonal antibodies cetu-
ximab [26,27] and panitumumab [28]. Crucially, HIFs
are also regulated by growth factor signalling, forexample EGF, suggesting that signalling cascades which
play key roles in CRC – namely EGFR activation and
HIFs – may converge. Increased HIF-1α protein and
transcriptional activity following EGFR stimulation in
various cell lines [29,30] was shown to be dependent
upon activation of receptor tyrosine kinases and down-
stream PI3K/Akt/MTOR [31-33]. However, the regula-
tion of HIFs by EGFR signalling in CRC, and the relative
importance of the contributions of HIFs towards a global
angiogenic response following EGFR activation, remain
unexplored. Furthermore, given that EGFR over-activity
and hypoxia are common features of solid tumours
[19,34], it is conceivable that they may interact to modu-
late expression of HIFs and thus affect angiogenic gene
responses in CRC.
In this study, we investigated whether EGF activated
HIF signalling in Caco-2 CRC cells. Caco-2 CRC cells are
an adherent cell line isolated from a patient with colo-
rectal adenocarcinoma. These cells express functional
wild-type EGFR [35], demonstrate responses to hypoxia
through HIF-1 and HIF-2 regulation [10], and are
frequently used as an in vitro model of CRC [36]. Further-
more, we examined the expression of a panel of angio-
genic genes following EGFR activation, to elucidate the
importance of HIF recruitment in mediating angiogenic
responses following EGFR activation. We found that the
HIF pathway was activated in Caco-2 CRC cells following
exposure to EGF, and in response to hypoxia and the
hypoxia mimetic dimethyloxalylglycine (DMOG). PCR
array profiling generated a distinctive angiogenic gene sig-
nature in response to hypoxia alone or DMOG alone, with
induction of angiopoietin (ANGPT) 1, angiopoietin like
(ANGPTL) 3, ANGPTL4, ephrin (EFN) A1, EFNA3,
FLT1, matrixmetalloprotease (MMP) 9, transforming
growth factor (TGF) β1 and VEGF. No difference was
observed between gene profiles induced by hypoxia versus
the hypoxia mimetic DMOG. We further characterised
the 4 candidate genes which were upregulated to the
greatest extent by hypoxia/DMOG – namely ANGPTL4,
EFNA3, TGF β1 and VEGF - to be hypoxia-regulated in
Caco-2 through the HIF-1α isoform. However, despite our
observation that EGF activated receptor autophosphory-
lation, HIF stabilisation and p42/p44 MAPK signalling,
angiogenic genes were unaltered by addition of EGF alone.
In contrast, addition of a combination of DMOG and EGF
did not further affect expression of the hypoxia/DMOG-
regulated angiogenic gene signature, but these combined
stimuli significantly upregulated expression of 11 ad-
ditional angiogenic genes. These findings suggest that
although EGF promotes HIF stabilisation in CRC, this is
not sufficient to induce angiogenic gene responses. In con-
trast, hypoxia and EGF synergise to additionally induce a
unique sub-group of candidate angiogenic genes, high-
lighting the complexity of the angiogenic process in CRC.
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Experimental protocols
Caco-2, a moderately differentiated adherent CRC cell line
(ATCC; Rockville, MD, USA) known to have non-
transformed EGFR [35] and HIF pathways [10], were
cultured in Eagle’s Minimum Essential Medium (EMEM)
(Biowhittaker, Lonza, Switzerland) containing non-essen-
tial amino acids and 1 mM sodium pyruvate. Medium was
supplemented with 1 mM Glutamine, 10% foetal bovine
serum (FBS), 100 U/mL streptomycin and 1.1 μg/mL
penicillin. For the experiments, Caco-2 cells were plated
in the above medium until cells achieved 50% confluence.
Cells were cultured for 24 hours in hypoxia (1% oxygen)
using a Galaxy R Incubator (Wolf Laboratories, York, UK)
or exposed to DMOG (dimethyloxaloylglycine; Biomol,
Plymouth Meeting, PA, USA), a cell-permeable PHD
inhibitor. Recombinant human EGF was purchased from
Peprotech, Rocky Hill, NJ, USA.
For transfection studies, Caco-2 cells (50% confluence)
were exposed to Lipofectamine and siRNA diluted in
Opti-MEM (Invitrogen, Carlsbad, CA, USA) for 6 hours
in serum-free EMEM. Subsequently, cells were supple-
mented with FBS, Glutamine and streptomycin/penicillin.
After a further 18 hours, cells were exposed to either 1%
O2 or 1 mM DMOG for 24 hours. siRNA sequences were
purchased from MWG (Ebersberg, Germany) and siLuc
was used as an irrelevant control: siHIF-1α 5′-[agcaguag
gaauuggaacauu]RNA [tt]DNA 3′, siHIF-2α 5′-[gcgacag
cuggaguaugaauu]RNA [tt]DNA 3′, siLuc 5′-[cguacgcggaa
uacuucga]RNA [tt]DNA 3′.
Analysis of gene expression by quantitative polymerase
chain reaction (Q-PCR)
RNA was extracted using the QIAamp RNA blood mini
kit (QIAGEN, GmbH, Germany) according to the manu-
facturer’s protocol, followed by Turbo DNAse treatment
(Ambion, Austin, USA). cDNA was synthesised using
MMLV reverse transcriptase, RNase H Minus, Point
Mutant (M-MLV RT (H-) and OligoDT primers (Promega,
Madison, USA). Subsequently, PCR was performed
using deoxynucleotide triphosphates (dNTPs), forward
and reverse primers and SYBR® Green JumpStart™ Taq
ReadyMix™ (Sigma-Aldrich, St Louis, MO, USA). The
primers were manufactured by MWG Biotech (Ebersberg,
Germany): acidic ribosomal phosphoprotein (ARP) Fwd:
5′-cgacctggaagtccaactac-3′, Rev: 5′-atctgctgcatctgcttg-3′;
HIF-1α: Fwd: 5′-cacctctggacttgcctttc-3′, Rev: 5′-ggctg
catctcgagactttt-3; HIF-2α: Fwd: 5′-ccttcaagacaaggtctgca-
3′, Rev: 5′-ttcatccgtttccacatcaa-3′; VEGF: Fwd: 5′-cttg
ccttgctgctctacct-3′, Rev: 5′-ctgcatggtgatgttggact-3′; ANGP
TL4: Fwd: 5′-ccacttgggaccaggatcac-3′, Rev: 5′-cggaagta
ctggccgttgag-3′; EFNA3: Fwd: 5′-cactctcccccagttcaccat-3,
Rev: 5′-cgctgatgctcttctcaagct-3′; TGFβ1: Fwd: 5′-gcaa
caattcctggcgatac-3, Rev: 5′-aagccctcaatttcccctc-3′; 18SFwd: 5′-gtaacccgttgaacccca-3′, Rev: 5′-ccatccaatcggtagta
gcg-3′.
The amplification, detection and quantification steps
were carried out using the Rotor-Gene 6000 centrifugal
thermal cycler (Corbett Research Mortlake, Sydney,
Australia). Gene expression was quantified using cycle
threshold (Ct) values by the comparative 2
-ΔΔCt method
[37], normalised to the housekeeping gene (HKG) 18S.
Comparable data were obtained when ARP was used as
HKG (not shown).
Analysis of gene expression by PCR-based angiogenesis
arrays
The Human Angiogenesis RT2 Profiler™ PCR Array
(SABiosciences, Frederick, MD, USA) was used to pro-
file the expression of 84 key genes involved in angioge-
nesis, with cDNA synthesised using the RT2 First Strand
Kit (SABiosciences, Frederick, MD, USA) according to
the manufacturer’s instructions. RNA from 3 experi-
ments was reverse transcribed and equal quantities of
the generated cDNA were pooled. Each experimental
condition was tested on duplicate PCR arrays using the
ABI PRISM 7700 Sequence Detector (Foster City, CA,
USA). Relative expression of various genes was calcu-
lated by the 2-ΔΔCt comparative method. Data were
normalised against the following HKG: 18S ribosomal
RNA, 60S ribosomal protein L13a (RPLP13A), β-actin
(ActB) and hypoxanthine phosphoribosyltransferase 1
(HPRT1). A gene expression fold-change threshold of
2.0 was applied, as previously described by our labo-
ratory [38]. Arrays were performed in duplicate on
2 separate occasions using pooled cDNA. To assess
the agreement between arrays, Bland-Altman statistical
tests were applied. No significant differences (p > 0.50 in
all cases) were observed when arrays performed on
different occasions were analysed. Furthermore, changes
in gene expression observed when arrays were per-
formed on 2 separate occasions correlated significantly:
DMOG-treated Caco-2 Spearman correlation co-efficient
0.42, p < 0.01, hypoxia-treated Caco-2 Spearman correl-
ation co-efficient 0.29, p < 0.05, DMOG plus EGF-treated
Caco-2 Spearman correlation co-efficient 0.49, p < 0.001.
Analysis of protein expression
For the HIF-1α ELISA, cells were harvested and lysed in
50 mM TRIS, 300 mM NaCl, 3 mM EDTA, 1 mM MgCl2,
25 mM NaF, 20 mM β-glycerophosphate, 1% Triton-X,
10% glycerol and protease inhibitor cocktail P-8340
(Sigma, St Louis, MO, USA). Total protein was quantified
by the Bicinchoninic assay (BCA) (Pierce, Rockford, USA).
The HIF-1α Duoset IC (R&D Systems, Minneapolis, USA)
was used to measure HIF-1α protein in total protein ly-
sates. Results were analysed using Ascent Version 2.6 soft-
ware (Thermo Fisher Scientific, Waltham, MA, USA).
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Figure 1 Scatter plot of PCR angiogenesis array analysis of
Caco-2 cells exposed to hypoxia and the hypoxia mimetic
DMOG. Caco-2 cells were exposed to either (a) hypoxia (1% O2) or
(b) DMOG (1 mM) for 24 hours. Scatter plot graphs are 2-ΔCt values
for genes expressed by Caco-2 and normalised against HKG ActB
(β-actin), 18S rRNA, HPRT1 (hypoxanthine phosphoribosyltransferase
1) and RPL13A (60S ribosomal protein L13a). Solid lines show no
change, dashed lines show ≥2-fold increase and decrease versus
untreated cells. Genes whose expression in both treated and
untreated samples was below detection limits of the array are not
included. Only genes whose expression changed ≥2-fold are anno-
tated. Data are from a representative array performed in duplicate
using cDNA pooled from 3 different replicate experiments.
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lysates from cells harvested and lysed with urea buffer
(8 M urea, 1% Sodium Dodecyl Sulphate, 1% glycerol and
10 mM Tris (pH6.8), 0.5 mM protease inhibitor cocktail
(Sigma-Aldrich, Poole, UK), 1 mM dithiothreitol) for
HIFs, or RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl,
1% Triton X, 0.1% SDS, 5 mM MgCl2, 50 mM NaF,
50 mM DTT, 2 mM orthovanadate, 5 mg/mL sodium
deoxycholate, 10 mM sodium pyrophosphate, 25 mM
β-glycerophosphate, 2 mM EDTA, 2 mM PMSF and pro-
tease inhibitor cocktail P-8340 (Sigma, St Louis, MO,
USA) for signalling studies. Samples were resolved on
SDS-polyacrylamide gels, where a 3-8% Tris-Acetate
NuPAGE® Novex gel (Invitrogen, Carlsbad, CA, USA) was
used for EGFR signalling studies, and a 4-12% Bis-Tris
NuPAGE® Novex gel (Invitrogen, Carlsbad, CA, USA) was
used for signalling and HIF-α protein studies. Rabbit
anti-human phospho EGFR (Tyr 1068), phospho EGFR
(Tyr 845), phospho p38 MAP Kinase (Thr 180/Tyr 182),
phospho p44/42 MAP Kinase (Thr 202/Tyr 204),
phospho-Akt (Ser 473), total EGFR, total p38 MAPK and
total p44/42 MAPK were from Cell Signaling Technology
(Danvers, MA, USA). Mouse anti-human HIF-1α and
HIF-2α (EPAS) were from Becton Dickinson (Franklin
Lakes, NJ, USA) and Santa Cruz Biotechnology (Santa
Cruz, CA, USA) respectively. Secondary anti-rabbit and
mouse HRP-conjugated antibodies were from Dako-
Cytomation (Glostrup, Denmark). Whole cell lysate of
EGF-treated A431 epithelial carcinoma cells used as posi-
tive control was from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Densitometry was performed using
Phoretix 1D analysis software (TotalLab Ltd, Newcastle
upon Tyne, UK).
Statistical analyses
Statistical significance was evaluated with 1-way ANOVA
with Dunnett’s post-hoc test to compare selected groups
of data. The ΔCt values were used to determine the sta-
tistical significance of differences between groups for
PCR-based studies. 2-way ANOVA with Bonferroni cor-
rection was used to compare selected groups of data with
respect to time.
Results
HIF-dependent induction of angiogenic genes in Caco-2
cells in response to hypoxia and the hypoxia mimetic
DMOG
Since hypoxia is likely to be a key stimulus for angioge-
nesis in CRC, we first investigated the angiogenic gene
profile of Caco-2 cells exposed to either hypoxia or the
hypoxia mimetic DMOG. Figure 1 and Table 1 illustrate
the Human Angiogenesis RT2 Profiler™ PCR array data
as scatter plots, and show that 9 pro-angiogenic genes
were significantly changed by a factor of at least 2.0-foldin response to either hypoxia (Figure 1a) or DMOG
(Figure 1b), including VEGF-A, known to be highly regu-
lated by hypoxia in various cell types (fold increase 3.1
and 3.4 in response to hypoxia and DMOG respectively).
Furthermore, 8 hypoxia-regulated genes were identified
Table 1 Genes included on the angiogenesis PCR array and expressed by Caco-2 cells
Symbol Gene name Description Stimulus
Hypoxia DMOG EGF EGF + DMOG
AKT1 PKB/PRKBA V-akt murine thymoma viral oncogene homolog 1 −1.1 1.3 1.2 1.1
ANGPT1 AGP1/AGPT Angiopoietin 1 2.3 2.1 1.6 2.3
ANGPTL3 ANGPT5 Angiopoietin-like 3 2.1 2.4 1.3 2.4
ANGPTL4 ANGPTL2/ARP4 Angiopoietin-like 4 3.1 3.9 1.4 5.8
ANPEP CD13/LAP1 Alanyl (membrane) aminopeptidase
(aminopeptidase N, aminopeptidase M, microsomal
aminopeptidase, CD13, p150)
1.5 1.3 −1.4 1.4
CCL11 SCYA11 Chemokine (C-C motif) ligand 11 1.9 1.1 1.5 3.5
CCL2 GDCF-2/GDCF-2 HC11 Chemokine (C-C motif) ligand 2 1.4 −1.5 1.6 1.4
COL18A1 KNO Collagen, type XVIII, alpha 1 1.8 1.2 1.0 1.3
COL4A3 TUMSTATIN Collagen, type IV, alpha 3 (Goodpasture antigen) 1.7 −1.1 1.3 2.2
EDG1 CHEDG1/D1S3362 Endothelial differentiation, sphingolipid G-protein-
coupled receptor 1, SIPR1
1.7 1.5 1.7 3.0
EFNA1 B61/ECKLG Ephrin-A1 2.6 2.4 1.0 2.0
EFNA3 EFL2/EPLG3 Ephrin-A3 7.2 6.6 1.3 4.9
EFNB2 EPLG5/HTKL Ephrin-B2 1.4 1.3 1.3 1.6
ENG CD105/END Endoglin 1.1 1.1 1.5 1.2
EPHB4 HTK/MYK1 EPH receptor B4 1.2 1.0 1.5 1.3
EREG ER Epiregulin 1.2 1.1 1.2 −1.9
FGFR3 ACH/CEK2 Fibroblast growth factor receptor 3 1.4 1.5 1.2 1.4
FLT1 FLT/VEGFR1 Fms-related tyrosine kinase 1 3.1 2.8 1.4 2.6
HIF1A HIF-1alpha Hypoxia-inducible factor 1, alpha −1.5 1.0 1.0 1.0
HPSE HPA/HPR1 Heparanase 1.7 1.9 1.1 1.8
ID1 ID Inhibitor of DNA binding 1, dominant negative
helix-loop-helix protein
−1.3 1.6 1.7 1.9
ID3 HEIR-1 Inhibitor of DNA binding 3, dominant negative
helix-loop-helix protein
1.5 −1.0 1.4 2.5
IGF1 IGFI Insulin-like growth factor 1 1.9 1.4 1.2 1.6
IL6 BSF2/HGF Interleukin 6 (interferon, beta 2) 1.9 1.3 1.5 1.7
IL-8 3-10C/AMCF-I Interleukin 8 1.9 −1.1 1.2 2.4
ITGAV CD51/MSK8 Integrin, alpha V (CD51) −1.1 1.4 1.9 1.9
ITGB3 CD61/GP3A Integrin, beta 3 (platelet glycoprotein IIIa, antigen
CD61)
1.3 −1.1 −1.2 2.4
JAG1 AGS/AHD Jagged 1 (Alagille syndrome) 1.1 1.6 1.6 2.7
KDR FLK1/VEGFR Kinase insert domain receptor 1.7 −1.2 −1.2 2.3
LAMA5 KIAA1907 Laminin, alpha 5 1.6 1.2 1.0 1.0
MMP2 CLG4/CLG4A Matrix metallopeptidase 2 (gelatinase A, 72kDa
gelatinase, 72kDa type IV collagenase)
1.7 1.5 −1.3 1.6
MMP9 CLG4B/GELB Matrix metallopeptidase 9 (gelatinase B, 92kDa
gelatinase, 92kDa type IV collagenase)
2.6 2.6 1.7 2.4
NOTCH4 INT3/NOTCH3 Notch homolog 4 (Drosophila) 1.5 −1.3 1.0 2.0
NRP1 DKFZp686A03134/DKFZp781F1414 Neuropilin 1 −1.6 −1.3 −1.5 −1.1
NRP2 NP2/NPN2 Neuropilin 2 −1.0 1.0 1.1 1.5
PDGFA PDGF-A/PDGF1 Platelet-derived growth factor alpha polypeptide 1.2 1.5 1.2 −1.2
PECAM1 CD31/PECAM-1 Platelet/endothelial cell adhesion molecule
(CD31 antigen)
1.61 −1.3 1.0 1.7
Khong et al. BMC Cancer 2013, 13:518 Page 5 of 17
http://www.biomedcentral.com/1471-2407/13/518
Table 1 Genes included on the angiogenesis PCR array and expressed by Caco-2 cells (Continued)
PLAU ATF/UPA Plasminogen activator, urokinase 1.4 1.4 1.4 1.7
PLXDC1 TEM3/TEM7 Plexin domain containing 1 1.9 1.0 1.7 1.8
SERPINF1 EPC-1/PEDF Serpin peptidase inhibitor, clade F (pigment
epithelium derived factor)
1.5 1.1 1.2 1.5
SPHK1 SPHK Sphingosine kinase 1 1.5 1.0 1.6 2.0
TGFA TFGA Transforming growth factor, alpha 1.9 1.4 1.5 2.3
TGFB1 CED/DPD1 Transforming growth factor, beta 1 5.4 4.3 1.4 4.6
TGFB2 TGF-beta2 Transforming growth factor, beta 2 1.7 1.0 1.0 1.8
TGFBR1 ACVRLK4/ALK-5 Transforming growth factor, beta receptor I (activin
A receptor type II-like kinase, 53 kDa)
1.6 1.5 1.3 1.6
THBS1 THBS/TSP Thrombospondin 1 1.3 1.2 1.0 1.0
THBS2 TSP2 Thrombospondin 2 1.1 1.0 −1.2 −1.1
TIMP1 CLGI/EPA TIMP metallopeptidase inhibitor 1 1.3 −1.2 −1.1 1.1
TIMP2 CSC-21K TIMP metallopeptidase inhibitor 2 1.5 −1.2 −1.3 −1.1
TNFAIP2 B94 Tumour necrosis factor, alpha-induced protein 2 1.7 1.2 −1.1 1.4
VEGF VEGFA/VPF Vascular endothelial growth factor 3.1 3.4 1.0 3.1
The Human Angiogenesis RT2 Profiler™ PCR Array was used to screen cDNA from Caco-2 cells exposed for 24 hours to either 1% O2, DMOG (1 mM), EGF
(10 ng/ml) or a combination of EGF plus DMOG. Data were compared to HKG: ActB (β-actin), 18S rRNA, HPRT1 (hypoxanthine phosphoribosyltransferase 1) and
RPL13A (60S ribosomal protein L13a), and are fold change versus untreated cells. Changes ≥2-fold are shown in bold. Data are from a representative array per-
formed in duplicate using cDNA pooled from 3 different replicate experiments.
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(ANGPT) 1 (fold increase 2.3 and 2.1 in response to
hypoxia and DMOG respectively), ANGPTL3 (fold in-
crease 2.1 and 2.4), ANGPTL4 (fold increase 3.1 and
3.9), ephrin (EFN) A1 (fold increase 2.6 and 2.4), EFNA3
(fold increase 7.2 and 6.6), VEGF receptor FLT1 (fold
increase 3.1 and 2.8), matrix metalloprotease (MMP) 9
(fold increase 2.6 and 2.6) and TGFβ1 (fold increase 5.4
and 4.3). None of the genes were downregulated in
response to treatment. A significant correlation was
observed between the fold-changes in gene expression
observed in hypoxia- versus DMOG-treated Caco-2
cells (Spearman correlation co-efficient 0.50, p < 0.001;
not shown), highlighting the high degree of concordance
between hypoxia- and DMOG-mediated responses in
Caco-2 CRC cells.
The genes whose expression changed the most dramati-
cally in response to hypoxia and DMOG were ANGPTL4,
EFNA3, TGFβ1 and VEGF. To determine their require-
ment for HIF isoforms, a small interfering (si) RNA
approach was used. Specific knockdown of HIF-1α and
HIF-2α, which we have previously demonstrated in other
cell types to markedly reduce HIF mRNA and protein
[38,39], was confirmed in Caco-2 at the mRNA level in
both DMOG- and hypoxia-stimulated cells, with 81% and
85% knockdown of HIF-1α mRNA in the presence of
siRNA against HIF-1α (compared with siLuc-transfected
Caco-2 cells), and 93% and 86% knockdown of HIF-2α
mRNA in the presence of siRNA against HIF-2α (data not
shown). There was no inhibitory effect of siHIF-1α on
HIF-2α, and vice versa (data not shown). Specificknockdown of HIF-1α and HIF-2α was also observed at
the protein level in cells exposed to hypoxia (Figure 2e)
and DMOG (Figure 3e).
Expression of ANGPTL4 was dependent on HIF-1α in
Caco-2 cells stimulated with either hypoxia or DMOG
(Figures 2a and 3a), with reductions of 83% (relative
to siLuc-transfected cells; p < 0.001) and 60% (p < 0.001)
respectively. In contrast, knockdown of HIF-2α was
without effect. Comparable data were observed for the
other genes in cells exposed to hypoxia, with knockdown
of HIF-1α, but not of HIF-2α, having a significant in-
hibitory effect. Thus for EFNA3, reductions of 54%
(p < 0.001; Figure 2b) and 43% (p < 0.05; Figure 3b) were
observed in response to hypoxia and DMOG res-
pectively in the presence of siHIF-1α. For TGFβ1, reduc-
tions of 60% (p < 0.001; Figure 2c) and 80% (p < 0.001;
Figure 3c) were observed in response to hypoxia and
DMOG respectively. Finally, in the case of VEGF, HIF-1α
knockdown resulted in reductions of 54% (p < 0.001;
Figure 2d) and 75% (p < 0.001; Figure 3d) in response to
hypoxia and DMOG respectively. These findings suggest
that HIF-1, but not HIF-2, mediates the induction of
angiogenic genes in CRC cells downstream of HIF activa-
tion in response to ether hypoxia or the hypoxia mimetic
DMOG.
Analysis of Caco-2 responses to EGF alone and in
combination with the hypoxia mimetic DMOG
Since we established that angiogenic gene induction was
HIF dependent in Caco-2 cells, we next investigated the
effect of EGF, alone or in combination with the hypoxia
Figure 2 Angiogenic gene expression in Caco-2 cells exposed to hypoxia is HIF-1 dependent. Caco-2 cells were transfected with siRNA
targeting luciferase (siLuc), HIF-1a (siHIF-1a) or HIF-2a (siHIF-2a), and subsequently exposed to hypoxia (1% O2) for 24 hours. Changes in (a) ANGPTL4,
(b) EFNA3, (c) TGFβ1 and (d) VEGF mRNA levels were determined by Q-PCR using the 2-ΔΔCt method and are expressed relative to HKG 18S. Data are
mean ± SEM from 3 representative experiments, and were analysed by 1-way ANOVA of ΔCt values versus siLuc: ns = not significant, *** p < 0.001.
Dashed line shows response of cells exposed to normoxia (21% O2). (e) Western blots, demonstrating specific HIF knockdown at the protein level, with
α-tubulin shown as loading control. N = normoxia, U = untransfected cells exposed to hypoxia.
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in Caco-2 cells. HIF-1α (Figure 4a) and HIF-2α (Figure 4b)
mRNA decreased modestly following stimulation with
either EGF, DMOG or a combination of both EGF and
DMOG stimulation, but these differences in level of
mRNA across all three groups over a period of 24 hours
were not statistically significant. In contrast, Western blotanalysis demonstrated a consistent up-regulation of both
HIF-1α and HIF-2α protein following DMOG or EGF
stimulation alone and in combination (Figure 4c). Analysis
using ELISA for HIF-1α confirmed the observation that
EGF resulted in a modest but statistically significant
increase in HIF-α protein levels, but addition of EGF to
DMOG did not further increase the HIF-1α response
Figure 3 Angiogenic gene expression in Caco-2 cells exposed to DMOG is HIF-1 dependent. Caco-2 cells were transfected with siRNA
targeting luciferase (siLuc), HIF-1α (siHIF-1α) or HIF-2α (siHIF-2α), or with lipofectamine alone (Mock), and subsequently exposed to DMOG (1mM)
for 24 hours. Changes in (a) ANGPTL4, (b) EFNA3, (c) TGFβ1 and (d) VEGF mRNA levels were determined by Q-PCR using the 2-ΔΔCt method and
are expressed relative to HKG 18S. Data are mean ± SEM from 3 representative experiments, and were analysed by 1-way ANOVA of ΔCt values
versus siLuc: ns = not significant, * p < 0.05, *** p < 0.001. Dashed line shows response of unstimulated cells. (e) Western blots, demonstrating HIF
knockdown at the protein level, with α-tubulin shown as loading control. N = normoxia, U = untransfected cells exposed to DMOG.
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HIF-1α protein levels were equivalent to 0.12 ± 0.04 pg/μg
total protein in unstimulated Caco-2 compared with
0.25 ± 0.05 pg/μg total protein in EGF-treated cells
(p < 0.05 versus untreated cells), compared to 0.74 ± 0.03
pg/μg total protein (p < 0.001) and 0.88 ± 0.18 pg/μg total
protein (p < 0.001) in cells exposed to DMOG alone or
DMOG in combination with EGF (Figure 4d).To investigate whether Caco-2 cells can respond to
EGF stimulation to activate other signalling pathways,
cells were exposed to EGF for different periods of time,
or left unstimulated. Figure 5a illustrates that a protein
band corresponding to phospho-EGFR was observed
following EGF stimulation, with marked phosphory-
lation of Tyr 945 in the intracellular signalling portion
of the receptor. The peak of receptor activation was seen
Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 HIF-α in Caco-2 cells exposed to EGF and/or DMOG. Caco-2 cells were stimulated with 20ng/mL EGF and/or 1mM DMOG for the
time periods indicated. Fold change in (a) HIF-1α and (b) HIF-2α mRNA levels were determined by Q-PCR using the 2-ΔΔCt method and are
expressed relative to HKG 18S. Data are mean ± SEM from 2 representative experiments. (c) HIF-1α and HIF-2α protein was measured by Western
blotting in Caco-2 cells stimulated with EGF and/or DMOG for 24 hours. α-tubulin is shown as a loading control. (d) HIF-1α protein was measured
by ELISA. Data are mean ± SEM from 3 representative experiments, and were analyzed by 2-way ANOVA versus unstimulated cells: *** p < 0.001.
15 30 60 120 15 30 60 120 A431















1.01 0.93 0.98 0.78 0.89 0.92 0.95 0.96 0.38
0.19 0.14 0.15 0.15 0.03 0.06 0.01 0.02 0.14
0.53 0.41 0.44 0.46 0.16 0.01 0.05 0.06 0.40
0.21 0.29 0.23 0.34 0.32 0.32 0.34 0.32 0.34
0.33 0.34 0.55 0.49 0.46 0.47 0.46 0.48 0.59
7.96 4.77 5.21 4.49 4.88 3.90 4.68 4.68 14.85
60.21 60.68 61.35 61.79 55.18 54.24 52.83 48.99 57.47
4.85 4.77 3.89 4.25 0.78 1.77 1.65 1.53 2.16
Figure 5 EGF receptor is autophosphorylated in Caco-2 and activates downstream signalling pathways. Caco-2 cells were stimulated with
20 ng/mL EGF for the time periods indicated. Western blotting for (a) phosphorylated EGFR or total EGFR and (b) antibodies recognising signal-
ling enzymes is shown. Cell lysate of EGF-treated A431 cells was used as positive control. α-tubulin is shown as a loading control. Densitometry
was performed using Phoretix 1D analysis software against α-tubulin (for ERK, data for p42 and p44 are shown).
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http://www.biomedcentral.com/1471-2407/13/51815–30 minutes following stimulation, and progressively
declined over the course of 60–120 minutes. Modest auto-
phosphorylation of Tyr 1068 following EGF stimulation
was also observed (data not shown).
Downstream signalling pathways known to play a role
in Caco-2 cells [40,41] were investigated as potential
signal transducers involved in initiating various intracel-
lular activities resulting from EGF-induced EGFR auto-
phosphorylation. Figure 5b confirms markedly higher
expression of phosphorylated p44 MAPK (ERK1) at Thr
202 and p42 MAPK (ERK2) at Tyr 204 in EGF-
stimulated versus control cells, which was maintained
even 2 hours after stimulation. The presence of anti-
phospho-p38 MAPK protein bands in both stimulated
and unstimulated cells suggests basal activation of p38
MAPK in Caco-2, which is not further increased by EGF
(although a very modest increase of less than 2-fold was
observed 15 minutes after EGF addition). Akt phos-
phorylation in Caco-2 cells was analysed and found to
be constitutively activated in Caco-2 cells (data not
shown).Figure 6 Angiogenic gene expression in Caco-2 cells exposed to EGF
and/or 1 mM DMOG for 24 hours. Changes in (a) ANGPTL4, (b) EFNA3, (c)
the 2-ΔΔCt method and are expressed relative to HKG 18S. Data are mean ±
ANOVA of ΔCt values versus normoxia (unless otherwise indicated): ns = no
unstimulated cells.Angiogenic gene profiling of Caco-2 cells following EGFR
activation
The above cell signalling studies clearly demonstrate that
EGF is capable of activating downstream signalling in
Caco-2 cells, inducing rapid phosphorylation of tyrosine
residues in EGFR, activation of ERK1/2 and stabilisation
of HIF proteins. However, in spite of the observed
changes, and in particular despite stabilisation of HIF-1α,
expression of the 4 angiogenic HIF-1 target genes, namely
ANGPTL4 (Figure 6a), EFNA3 (Figure 6b), TGFβ1
(Figure 6c) and VEGF (Figure 6d), was unaffected by
addition of EGF alone. Furthermore, responses induced by
DMOG alone were not further altered by addition of EGF
(p > 0.05 versus DMOG alone) specifically for these 4
angiogenic genes.
The Human Angiogenesis RT2 Profiler™ PCR Array
was used to examine the expression of a panel 84 esta-
blished angiogenic genes in cells exposed to either EGF
alone or in combination with DMOG. None of the genes
which were detected on the array demonstrated sig-
nificant change in expression (either upregulation orand/or DMOG. Caco-2 cells were stimulated with 20 ng/mL EGF
TGFβ1 and (d) VEGF mRNA levels were determined by Q-PCR using
SEM from 3 representative experiments, and were analysed by 1-way
t significant, *** p < 0.001. Dashed line shows response of
Figure 7 Scatter plot PCR array analysis of Caco-2 cells exposed
to EGF alone or in combination with DMOG. Caco-2 cells were
stimulated with 20 ng/mL EGF for 24 hours alone (a) or in combination
with 1mM DMOG (b). Scatter plot graphs are 2-ΔCt values for genes
expressed by Caco-2 and normalised against HKG ActB (β-actin), 18S
rRNA, HPRT1 (hypoxanthine phosphoribosyltransferase 1) and RPL13A
(60S ribosomal protein L13a). Solid lines show no change, dashed lines
show ≥2-fold increase and decrease versus untreated. Genes whose
expression in both treated and untreated samples was below detec-
tion limits of the array are not included. Only genes whose expression
changed ≥2-fold are annotated, with annotated open circles represen-
ting the 9 genes also changed in response to hypoxia and DMOG, and
annotated closed circles representing the 11 additional genes uniquely
changed only in response to DMOG plus EGF. Data are from a repre-
sentative array performed in duplicate using cDNA pooled from 3
different replicate experiments.
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and Table 1). Combined DMOG and EGF did not further
induce expression of the 9 genes previously shown to be
upregulated by DMOG alone or hypoxia alone (ANGPT1,
ANGPTL3, ANGPTL4, EFNA1, EFNA3, FLT1, MMP9,
TGFβ1 and VEGF, Figure 7b and Table 1). Nevertheless,
the combined stimuli induced a unique profile of 11
additional angiogenic genes which were not altered by
either hypoxia alone, DMOG alone or EGF alone. Spe-
cifically, expression of chemokines CCL11 (eotaxin-1;
3.5-fold increase) and IL8 (2.4-fold), together with EDG1
(endothelial differentiation gene 1 or sphingolipid G-
protein-coupled receptor 1; 3.0-fold increase), DNA-
binding protein inhibitor ID3 (2.5-fold increase), Jagged
1 (known also as CD339; 2.7-fold increase), VEGF
receptor KDR (2.3-fold increase), NOTCH4 (2.0-fold in-
crease), SPHK1 (sphingosine kinase 1; 2.0-fold increase)
and TGFα (2.3-fold increase) was altered in response to
EGF plus DMOG (Figure 7b and Table 1). Furthermore,
expression of COL4A3 was also increased (2.2-fold)
in Caco-2 exposed to the combination of EGF plus
DMOG, as were levels of integrin β3 chain (2.4-fold).
These findings demonstrate that there are 2 unique
gene signatures in Caco-2 cells, namely a set of 9 genes
affected by hypoxia/DMOG alone, and a further set of
11 genes induced only by combined EGF and DMOG
stimulation.
Discussion
CRC is the third most common cancer worldwide, and
in the European Union alone, the lifetime estimated risk
of developing the disease is 6%. Over the last 30 years,
advances in diagnostic tools and a consensus towards
internationally standardised staging criteria of the con-
dition, together with combined multimodal treatment
strategies, have contributed to substantial improvement
in 5 year survival rates for patients with CRC, from 22%
to 50% [42]. Crucially, recent advances in understanding
molecular mechanisms driving tumours have increased
our understanding of the mechanisms underlying the
benefits of new treatment agents which selectively target
abnormal pathways confined to tumours, allowing im-
provements in the prognosis of patients with advanced
CRC and development of new therapeutic modalities.
Deciphering the complex biological mechanisms under-
lying tumour angiogenesis has been a major focus of
research, as the growth of solid tumours is restricted
to 2-3 mm3 in size without neo-vascularisation [43].
Hypoxia, a feature common to most solid tumours, has
been established as a promoter of angiogenesis by modu-
lating expression of several mediators, particularly VEGF,
cell adhesion molecules and surface receptors. However,
hypoxia-regulated candidate genes specifically relevant to
CRC angiogenesis have not been examined in detail.
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patient with colorectal adenocarcinoma. Their capacity to
differentiate into a polarised monolayer of mature
enterocyte-like cells on reaching confluence, which has
led to their adoption as a standard model for in vitro
studies of enteric drug absorption and transport [44],
and their widespread used as an in vitro model of CRC
[36,41,45,46]. In common with approximately 50% of
colorectal tumours, Caco-2 cells have a mutant p53 onco-
gene, which is known to be associated with increased
VEGF production [47]. Caco-2 cells contain the wild-type
of two other oncogenes, K-ras and BRAF [48,49], muta-
tions of which are present in 45% and 15% of colorectal
tumours respectively [49,50]. Furthermore, Caco-2 express
receptors for EGF and release VEGF in response to num-
ber of stimuli including hypoxia and K-ras [14,51-53].
Inappropriate mucin gene expression is also related
to CRC development, invasiveness and prognosis, and
mucin-5AC, which is expressed in large amounts in
Caco-2 cells, has been observed in the early stages of
the colorectal adenoma-carcinoma sequence [49,54]. In
addition, Claudin-2, a unique member of the claudin
family of transmembrane proteins which is significantly
increased in CRC and correlates with cancer progression
and tumour growth, is regulated in Caco-2 via EGF [55].
Caco-2 tumourigenicity has been demonstrated by the
development of moderately-well differentiated adenocar-
cinoma in vivo following inoculation into mice [56]. Use
of Caco-2 cells thus allows elucidation of mechanisms of
disease pathogenesis, including angiogenesis [57,58], with
pathway-based analysis likely to yield valuable information
at the molecular level that would contribute to our under-
standing of the development of CRC.
The present study identified VEGF-A, known to be
regulated by hypoxia in other cell types, as a hypoxia-
responsive gene in CRC cells, together with 8 additional
hypoxia-regulated genes namely ANGPT1, ANGPTL3,
ANGPTL4, EFNA1, EFNA3, VEGF receptor FLT1, MMP9
and TGFβ1. An identical angiogenic gene signature rele-
vant to CRC was elicited following treatment of Caco-2
with the pan-specific HIF hydroxylase inhibitor and HIF
activator DMOG. Genes with the highest change in ex-
pression following hypoxia or DMOG stimulation, namely
ANGPTL4, EFNA3, TGFβ1 and VEGF, were selected for
studies using RNA knockdown. Previous studies have
demonstrated that hypoxic induction of VEGF in Caco-2
cells was in part due to HIF-1α, but this study did not
detect significant levels of HIF-2α [14]. A study by
Zgouras et al. showing that HIF-1α regulates butyrate-
induced normoxic VEGF expression in Caco-2 cells did
not investigate the possible involvement of HIF-2α [57],
and while studies have linked HIF-1α expression with
apoptosis in Caco-2, none examined the role of HIF-2α
[17,59]. In our study, the increase in ANGPTL4,EFNA3, TGFβ1 and VEGF expression by hypoxia was
significantly inhibited following knockdown of HIF-1α,
with little or no contribution of HIF-2α. Thus, we have
established a unique set of angiogenic genes which were
hypoxia-regulated in CRC Caco-2 cells, and confirmed
an identical expression profile with DMOG stimulation,
as well as the dependence of angiogenic responses on
HIF-1 by RNA knockdown studies.
In addition to the oxygen-dependent regulation of HIF-α
by hypoxia and hypoxia mimetics such as DMOG, sig-
nalling by growth factors including EGFR activation has
been shown to induce HIF-1α expression in other cell
types under normoxic conditions [60]. The key role
of EGF/EGFR in CRC has been demonstrated by the
successful development of EGFR-targeted therapies cetu-
ximab and panitumumab. Our study confirmed that EGFR
autophosphorylation is associated with HIF-1α and HIF-2α
protein stabilisation under normoxia in Caco-2 cells.
Unlike the effect of hypoxia on protein stability due to the
inactivity of oxygen-dependent HIF hydroxylases, the
observed increase in HIF-α protein is most probably
attributed to post-transcriptional responses, such as in-
creased stability or post-translational modifications, since
mRNA levels of HIF-1α and HIF-2α were not increased
by EGF. A study on breast cancer cells where HER2 sig-
nalling specifically induced HIF-1α protein expression
without affecting HIF-1α mRNA showed the response
was dependent upon activation of the PI3K/Akt/FRAP
thus increasing rate of protein synthesis [31]. Other stu-
dies have also reported increased HIF-1α translation me-
diated through PI3K/Akt [33,61]. In order to investigate
the involvement of a similar signalling pathway, we exa-
mined activation of EGFR, ERK and p38 MAPK and Akt.
Our study on Caco-2 cells illustrated selective activation
of MAPK ERK1/2 signalling, in contrast to PI3K/Akt and
P38 MAPK which remained constitutively active irrespec-
tive of exogenous EGFR stimulation.
Since EGFR activation led to HIF upregulation in
Caco-2 cells, a response analogous to that observed with
hypoxia or DMOG, we predicted that EGFR-induced
angiogenic gene profile would parallel that induced by
hypoxia or DMOG. Such findings would lend further
impetus towards developing novel anti-EGFR agents
such as the monoclonal antibodies cetuximab and pani-
tumumab [26,28]. The next part of our study therefore
aimed to decipher the global involvement of known an-
giogenic genes in modulating the tumour microenviron-
ment. Unexpectedly, our data showed that none of the
84 angiogenic genes were affected by EGFR activation,
in spite of induction of downstream ERK MAPK signal-
ling and stabilisation of HIF-α. The absence of effect of
EGF alone was also validated by Q-PCR for ANGPTL4,
EFNA3, TGFβ1 and VEGF, genes which demonstrated
significant upregulation in a HIF-1-dependent manner
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ever, both EGFR over-activation and hypoxia typically
co-exist within the tumour microenvironment and both
may impact upon the differential modulation of angio-
genic responses induced by either stimulus. We therefore
examined the effect of simultaneous stimulation of Caco-2
CRC cells using EGF and the HIF activator DMOG.
Our data demonstrated that the previously established
hypoxia-regulated angiogenic genes (ANGPT1, ANGPTL3,
ANGPTL4, EFNA1, EFNA3, FLT1, MMP9, TGFβ1 and
VEGF) were not further affected by addition of EGF. Im-
portantly, we have instead identified an additional sub-set
of genes which were only expressed following combined
EGF and DMOG, and not with either EGF alone or
DMOG/hypoxia alone. The unique profile of 11 additional
angiogenic genes which were only expressed with com-
bined EGF and DMOG includes chemokines CCL11
(eotaxin-1) and IL8, EDG1 (endothelial differentiation
gene 1 or sphingolipid G-protein-coupled receptor 1),
DNA-binding protein inhibitor ID3, Jagged 1 (JAG1
known also as CD339), VEGF receptor KDR, NOTCH4,
SPHK1 (sphingosine kinase 1, which extracellularly acts as
a ligand for EDG1) and TGFα. Furthermore, expression of
COL4A3 (tumstatin, an angiogenesis inhibitor which is a
cleavage fragment of collagen IV α3 NC1 domain) was
also increased in Caco-2 exposed to the combination of
EGF plus DMOG, as were levels of integrin β3 chain,
which together with αV integrin binds tumstatin via an
RGD-independent mechanism. As both EGFR [20] and
hypoxia [6] are inducers of angiogenesis, these results sug-
gest a novel and previously unreported synergistic rela-
tionship which culminates in a downstream response that
supersedes the angiogenic effect exerted by either of the
stimuli in isolation. This synergistic effect may be ex-
plained by the positive influence of activated ERK MAPK
downstream of EGFR on the activity of HIF complexes by
enhancing recruitment of p300/CREB-binding protein
(CBP), thus completing the formation of functionally
active transcription complexes to transactivate hypoxia
response elements of select genes [62]. However it re-
mains unclear why a similar response is not elicited in
Caco-2 following EGFR activation alone, given that HIF
expression was significantly upregulated (paralleling that
following DMOG treatment) and downstream ERK
MAPK signalling was activated. It is conceivable that
despite activated EGFR increasing expression of HIF, this
transcription factor is functionally inactive due to the
activity of HIF hydroxylase enzymes such as factor inhibi-
ting HIF-1 (FIH-1), which interferes with the ability of
HIF to initiate transcription. Under normoxic conditions,
hydroxylation of the asparagine residue 803 in the
carboxyl-terminal transcriptional activation domain of
HIF abrogates interactions with the transcriptional co-
activators p300 and CBP [63]. Translation of resultsfrom our study to the clinical setting suggests that
inhibition of angiogenesis with EGFR antagonists may
be better targeted at select tumours which are particu-
larly hypoxic.
The precise roles of ANGPTL4, EFNA3 and TGFβ1,
and the 11 unique genes induced by EGF plus DMOG
which are not induced by DMOG or hypoxia alone, in
regulating CRC angiogenesis remain unknown. ANGPTL4
is a member of a family of seven molecules bearing struc-
tural homology to angiopoietins [64], and appears to
mediate both pro- and anti-angiogenic effects, with the
eventual outcome determined by cell-specific contexts
and interactions with other angiogenic factors [65-67]. Of
relevance, a recent study has reported that expression of
ANGPTL4 correlates with the depth of tumour invasion,
venous invasion and Duke’s classification in CRC [68].
EFNA3 was another novel gene identified as being upre-
gulated by DMOG and hypoxia in Caco-2 cells. Ephrins
and their cognate receptor tyrosine kinases regulate cell
migration and adhesion, and thereby influence cell lineage,
morphogenesis and organogenesis [69,70]. In adult life,
ephrin upregulation, particularly of ephrin B, has been
correlated to vascular invasion, blood vessel formation
and sprouting by tumours, and soluble Eph A receptors
have been shown to inhibit tumour angiogenesis [71]. The
role of EFNA3 in CRC angiogenesis remains unproven,
although ephrin and Eph receptor over-expression has
been reported in a variety of human cancers including
CRC [72,73]. TGFβ has a multifaceted homeostatic role in
regulating cell growth and differentiation, angiogenesis,
immune function and extracellular matrix formation [74].
Overexpression of TGFβ1 in primary CRC is a poor
prognostic predictor and correlated with advanced stage
of disease, increased risk of recurrence, shorter post-
operative survival, particularly in early tumours and de-
creased overall survival [75,76]. Regulation of TGFβ1
expression by tissue oxygenation remains unstudied in
CRC, although HIF-1α has been shown to increase TGFβ
expression in prostate cancer cells [77]. Immunohisto-
chemical studies have demonstrated a correlation bet-
ween TGFβ and VEGF expression, where CRC tissues
with the highest microvessel density expressed both
growth factors [78].
Although the focus of the study was to investigate the
angiogenic responses induced by EGFR, the receptor,
being a member of the ErbB family of receptor tyrosine
kinases, also has influence over numerous cellular pro-
cesses by triggering multiple signalling cascades. EGFR
signalling promotes DNA synthesis and cell cycle pro-
gression by recruiting downstream MAPK, STAT pro-
teins, SRC family and Akt protein kinases, which can
induce transcription of genes involved in cell growth,
division, differentiation and survival [79-82]. Pre-clinical
and clinical data show that aberrant EGFR and
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which can lead to sustained proliferation of abnormal ma-
lignant cells [82-84]. Furthermore, stimulation of EGFR
pathways has been shown to promote tumour cell inva-
sion, motility, adhesion and metastasis [85,86]. Despite the
inability to demonstrate angiogenic gene responses follo-
wing EGFR activation in our study, EGFR remains an
important feature as preclinical and clinical studies have
demonstrated efficacy of EGFR inhibitors in advanced
CRC, particularly in combination with chemo- and radio-
therapy [87,88].
Conclusion
In summary, we have identified three novel HIF-1α-
regulated angiogenic genes in Caco-2 cells, of which two,
ANGPTL4 and TGFβ1, are associated with worse out-
come in patients with CRC. In this regard, it is relevant
that we have recently observed that primary cells isolated
enzymatically from tumour resections obtained from pa-
tients with CRC also upregulate expression of VEGF,
EFNA3, TGFβ1 and ANGPTL4 when exposed to hypoxia,
supporting the relevance of studies using Caco-2 cells to
understand the mechanisms underlying CRC progression
and underlining the potential importance of these angio-
genic genes in CRC [89-91]. We subsequently studied
Caco-2 responses to EGF, the action of which is inhibited
by successful CRC treatments, that is anti-EGFR anti-
bodies cetuximab and panitumumab. However, despite
our finding that EGFR autophosphorylation led to select-
ive downstream activation of p42/p44MAPK and HIF pro-
tein stabilisation, this was not sufficient to induce
angiogenic gene responses in CRC cells. In contrast, EGF
synergised with the hypoxia mimetic DMOG to induce
the expression of a unique subset of angiogenic genes.
Our findings support a key role for tissue hypoxia in eli-
citing angiogenic gene responses in CRC cells, also in
combination with EGF, and highlight the complex inter-
relationship between tumour hypoxia, EGF and angio-
genesis in the pathogenesis of CRC.
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